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ABSTRACT
Previous work has provided strong evidence
for a role of peroxisome proliferator-activated
receptor b/d (PPARb/d) and transforming growth
factor-b (TGFb) in inflammation and tumor stroma
function, raising the possibility that both signaling
pathways are interconnected. We have addressed
this hypothesis by microarray analyses of human
diploid fibroblasts induced to myofibroblastic differ-
entiation, which revealed a substantial, mostly
reverse crosstalk of both pathways and identified
distinct classes of genes. A major class
encompasses classical PPAR target genes,
including ANGPTL4, CPT1A, ADRP and PDK4.
These genes are repressed by TGFb, which is coun-
teracted by PPARb/d activation. This is mediated, at
least in part, by the TGFb-induced recruitment of the
corepressor SMRT to PPAR response elements, and
its release by PPARb/d ligands, indicating that TGFb
and PPARb/d signals are integrated by chromatin-
associated complexes. A second class represents
TGFb-induced genes that are downregulated
by PPARb/d agonists, exemplified by CD274 and
IL6, which is consistent with the anti-
inflammatory properties of PPARb/d ligands.
Finally, cooperative regulation by both ligands was
observed for a minor group of genes, including
several regulators of cell proliferation. These obser-
vations indicate that PPARb/d is able to influ-
ence the expression of distinct sets of both
TGFb-repressed and TGFb-activated genes in both
directions.
INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
nuclear receptors that function as ligand-inducible tran-
scription factors (1–3). The three PPAR subtypes
(PPARa, PPARb/d and PPARg) activate their target
genes through binding to PPAR response elements
(PPREs) as heterodimers with members of the retinoid
X receptor (RXR) family. PPARs play a central role in
lipid metabolism by serving as sensors for fatty acids and
fatty acid metabolites with major function as modulators
of metabolic and inﬂammatory processes. Consequently,
the transcriptional activity of PPARs is modulated not
only by natural fatty acids, but also by lipid-derived me-
tabolites such as prostaglandins J2 and I2, leukotriene A4,
15-hydroxyeicosatetraenoic acid and 1-palmitoyl-2-
oleoyl-sn-glycerol-3-phosphocholine (4–7). PPARs also
play essential roles in developmental processes, wound
healing, cell differentiation and proliferation and many
associated diseases, including arteriosclerosis, diabetes,
ﬁbrosis, inﬂammatory disorders and cancer (8–12),
which led to the development of numerous subtype-
selective, high-afﬁnity ligands (13).
We and others have shown that PPARb/d plays an es-
sential role in regulating the differentiation, function and
proliferation of tumor stroma cells (14–16). Ppard-null
mice show gross alterations of tumor endothelial cells
and ﬁbroblasts, resulting in a high proportion of
immature, dysfunctional microvessels and increased
numbers of myoﬁbroblastic cells (14). Consistent with
these in vivo data, overexpression of PPARb/d inhibited
the proliferation of cultured ﬁbroblasts (14). Likewise, the
prostacyclin mimetic Treprostinil inhibited the prolifer-
ation of lung ﬁbroblasts concomitant with the transcrip-
tional activation of PPARb/d (17). A regulatory role for
PPARb/d in myoﬁbroblasts has also been shown in a cell
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ﬁbroblasts induced to myoﬁbroblast transdifferentiation
by culturing on a rigid substrate (18). Finally, different
PPAR subtypes have been shown to play a role in experi-
mentally induced lung ﬁbrosis, and it has been sug-
gested that PPARb/d agonists may attenuate disease
progression by inhibiting myoﬁbroblast proliferation and
function (19).
A cytokine present in vast amounts in many tumors and
playing a pivotal role in both tumor stroma function, in-
ﬂammation and tissue ﬁbrosis is the transforming growth
factor-b (TGFb) (20), suggesting that PPARb/d and
TGFb signaling pathways may functionally interact. To
test this hypothesis, we performed microarray analyses of
human lung ﬁbroblasts induced to differentiate into
myoﬁbroblastic cells by TGFb and analyzed the inﬂuence
of PPARb/d agonists on the transcriptional proﬁle. This
study revealed an extensive, mainly reverse crosstalk of the
transcriptional pathways regulated by PPARb/d and
TGFb, leading to the deﬁnition of distinct classes of
genes. Class A genes are repressed by TGFb, which is,
at least in part, due to the induction of the corepressor
SMRT and is counteracted by PPARb/d agonists. These
include many known PPAR target genes with functions in
lipid metabolism. A prominent example is the ANGPTL4
gene, which encodes an important regulator of lipid me-
tabolism and presumptive modulator of metastasis
(21,22). In contrast, class B genes are induced by TGFb
and downregulated by PPARb/d agonists. These genes
include IL6, which may be relevant in view of the
reported anti-inﬂammatory and anti-ﬁbrotic properties
of PPARb/d.
MATERIALS AND METHODS
Chemicals
TGFb1 was purchased from Sigma-Aldrich (Karlsruhe,
Germany), GW501516, GW1929 and GW7647 from
Axxora (Lo ¨ rrach, Germany), and L165,041 from
Calbiochem (Merck, Darmstadt, Germany).
Cell culture
WI-38 cells were obtained from the ATCC and maintained
in DMEM/MCDB105 (1:1, PAA, Co ¨ lbe, Germany/
Sigma, Steinheim, Germany) supplemented with 10%
fetal bovine serum, 100U/ml penicillin and 100mg/ml
streptomycin in a humidiﬁed incubator at 37 C and 5%
CO2. Differentiation by TGFb1 was carried out in
serum-free medium as described (23,24).
Immunostaining and quantiﬁcation of stress ﬁbers
Cells were ﬁxed with ethanol (70%), stained by indirect
immunoﬂuorescence using a polyclonal a-SMA antibody
(Sigma, Steinheim, Germany) visualized by a Cy5-labeled
secondary antibody (Molecular Probes A11029,
Invitrogen, Karlsruhe, Germany), and counterstained
with Hoechst 33258 (Invitrogen). Slides were evaluated
with a Leica RMB 3 microscope equipped with ﬂuores-
cence optics. For quantitative evaluation of SMA stress
ﬁbers detected by immunoﬂuorescence, cells showing
strong, weak or no staining were counted separately. A
total of  750 cells in eight microscopic ﬁelds were
counted per sample.
Small-interfering RNA transfections
Cells were seeded at a density of 5 10
5 cells per 6cm dish
in 4ml DMEM with 10% fetal calf serum (FCS) and
cultured for 2h. 1280ng small-interfering RNA (siRNA)
in 100ml OptiMEM (Invitrogen) and 20ml HiPerfect
(Qiagen, Hilden, Germany) were mixed and incubated
for 5–10min at room temperature prior to transfection.
The cells were replated 24h post-transfection at a density
of 5 10
5 cells per 6cm dish. Transfection was repeated
48h after start of the experiment, and cells were passaged
after another 24h. Forty-eight hours following the last
transfection, cells were incubated in serum-free medium
for 24h before stimulation. The NCOR2 siRNA pool
was composed of the following sequences:
Hs_NCOR2_1: 50-GGA CGG AGA UCU UCA AUA U;
Hs_NCOR2_2: 50-GAA CCU CGA UGA GAU CUU G;
Hs_NCOR2_3: 50-GGA AAA GAC UCA AAG UAA A;
Hs_NCOR2_4: 50-GCG CAC CUA UGA CAU GAU G;
control siRNA (#1022563, Qiagen, Hilden, Germany).
Quantitative real-time polymerase chain reaction
Complementary DNA (cDNA) was synthesized from
0.1–1mg of RNA using oligo(dT) primers and the
Omniscript kit (Qiagen, Hilden, Germany). Quantitative
polymerase chain reaction (qPCR) was performed in a
Mx3000P Real-Time PCR system (Stratagene, La Jolla,
CA, USA) for 40 cycles at an annealing temperature of
60  C. PCR reactions were carried out using the Absolute
QPCR SYBR Green Mix (Abgene, Hamburg, Germany)
and a primer concentration of 0.2mM following the manu-
facturer’s instructions. L27 was used as normalizer.
Comparative expression analyses were statistically
analyzed by Student’s t-test (two-tailed, equal variance)
and Bonferroni correction. The sequences of the primers
are as follows:
ANGPTL4fw: 50-GATGGCTCAGTGGACTTCAACC;
ANGPTL4rv: 50-CCCGTGATGCTATGCACCTTC;
L27fw: 50-AAAGCCGTCATCGTGAAGAAC;
L27rv: 50-GCTGTCACTTTCCGGGGATAG;
PPARDfw: 50-TCATTGCGGCCATCATTCTGTGTG;
PPARDrv: 50-TTCGGTCTTCTTGATCCGCTGCAT;
ADRPfw: 50-TGTGAGATGGCAGAGAACGGT;
ADRPrv: 50-CTGCTCACGAGCTGCATCATC;
CPT1Afw: 50-ACAGTCGGTGAGGCCTCTTATGAA;
CPT1Arv: 50-TCTTGCTGCCTGAATGTGAGTTGG;
PDK4fw: 50-TTGAGTGTTCAAGGATGCTCTG;
PDK4rv: 50-TGCCCGCATTGCATTCTTAAATA;
COL4A1fw: 50-ACTCTTTTGTGATGCACACCA;
COL4A1rv: 50-AAGCTGTAAGCGTTTGCGTA;
ACTA2fw: 50-TGATCACCATCGGAAATGAA;
ACTA2rv: 50-TGATGCTGTTGTAGGTGGTTTC;
SM22Afw: 50-TTGAAGGCAAAGACATGGCAG;
SM22Arv: 50-CCATCTGAAGGCCAATGACAT;
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ANGPTL4rv: 50-CCCGTGATGCTATGCACCTTC;
L27fw: 50-AAAGCCGTCATCGTGAAGAAC;
L27rv: 50-GCTGTCACTTTCCGGGGATAG;
PPARDfw: 50-TCATTGCGGCCATCATTCTGTGTG;
PPARDrv: 50-TTCGGTCTTCTTGATCCGCTGCAT;
ADRPfw: 50-TGTGAGATGGCAGAGAACGGT;
ADRPrv: 50-CTGCTCACGAGCTGCATCATC;
CPT1Afw: 50-ACAGTCGGTGAGGCCTCTTATGAA;
CPT1Arv: 50-TCTTGCTGCCTGAATGTGAGTTGG;
PDK4fw: 50-TTGAGTGTTCAAGGATGCTCTG;
PDK4rv: 50-TGCCCGCATTGCATTCTTAAATA;
COL4A1fw: 50-ACTCTTTTGTGATGCACACCA;
COL4A1rv: 50-AAGCTGTAAGCGTTTGCGTA;
ACTA2fw: 50-TGATCACCATCGGAAATGAA;
ACTA2rv: 50-TGATGCTGTTGTAGGTGGTTTC;
SM22Afw: 50-TTGAAGGCAAAGACATGGCAG;
SM22Arv: 50-CCATCTGAAGGCCAATGACAT;
CD274fw: 50-GGCATCCAAGATACAAACTCAA;
CD274rv: 50-CAGAAGTTCCAATGCTGGATTA;
CLDN1fw: 50-CCCTATGACCCCAGTCAATG;
CLDN1rv: 50-ACCTCCCAGAAGGCAGAGA;
IL6fw: 50-CAGGAGCCCAGCTATGAACT;
IL6rv: 50-AGCAGGCAACACCAGGAG;
NCOR1fw: 50-TCGCTTCCACTGTTTCTGC;
NCOR1rv: 50-GGGCTTGACAGCTTCAACTT;
NCOR2fw: 50-CGGAGTGACCACACACTCAC;
NCOR2rv: 50-GGGTCTGCCAGAGACCTTG.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as
described (6), except that nuclei were resuspended at
2.5 10
7/ml, and 60 pulses were applied during sonic-
ation. The following antibodies were used: IgG pool,
I5006 (Sigma-Aldrich, Steinheim, Germany), a-PPARb/
d, sc-7197 (Santa Cruz, Heidelberg, Germany); a-SMRT,
ab24551 (Abcam, Cambridge, UK). Comparative binding
analyses were statistically analyzed by Student’s t-test
(two-tailed, equal variance) and corrected for multiple hy-
pothesis testing by the Bonferroni method. Primer se-
quences were as follows:
ANGPTL4+3500fw: 50-CCTTACTGGATGGGAGGAAAG;
ANGPTL4+3500rv: 50-CCCAGAGTGACCAGGAAGAC;
ANGPTL4-12000fw: 50-ACCCTGGGTGTTCATGGTAG;
ANGPTL4-12000rv: 50-CCCAAGGGGTTCAATGTATTC.
Microarrays
RNA was isolated using the Nucleospin RNA II kit
(Macherey-Nagel, Du ¨ ren, Germany). RNA quality was
assessed using the Experion automated electrophoresis
station with RNA StdSens chips (Bio-Rad, Munich,
Germany). For microarray studies, total RNA samples
were ampliﬁed and labeled using the Agilent Quick Amp
Labeling Kit (Agilent, Santa Clara, CA, USA) according
to the manufacturer’s instructions. The ampliﬁcation pro-
cedure consists of reverse transcription of total RNA,
including spike-in with an oligo(dT) primer bearing a T7
promoter, followed by in vitro transcription of the
resulting cDNA with T7 RNA polymerase in the
presence of dye labeled CTP to generate multiple ﬂuores-
cence labeled copies of each messenger RNA (mRNA).
After puriﬁcation, the labeled aRNA was quantiﬁed and
hybridization samples were prepared according to the
manufacturer’s instructions. Human Agilent 4-plex
Array 44K were used for the analysis of the gene expres-
sion of the different samples in a reference-design assay.
As a reference, a pool of all samples was used. This refer-
ence was labeled with Cy3, while the samples were labeled
with Cy5 dye. The hybridization assembly was performed
as described in the Agilent Microarray Hybridization
Chamber User Guide (G2534-90001). After a 17-h hybrid-
ization at 65 C, slides were washed as described by the
manufacturer and subsequently scanned using an Agilent
DNA Microarray Scanner G2505C; scan software:
Agilent Scan Control Version A.8.1.3; quantiﬁcation
software: Agilent Feature Extraction Version 10.5.1.1
(FE Protocol GE_105_Dec08). Raw microarray data
were normalized using the ‘loess’ method implemented
within the marray package of R/BioConductor
(www.bioconductor.org). Regulated probes were selected
on the basis that the logarithmic (base 2) average intensity
value was  6, and that the ﬂuctuation between replicates
was  50%.
RESULTS
Induction of myoﬁbroblastic differentiation of diploid
human ﬁbroblasts
The purpose of the present study was to investigate
whether PPARb/d and TGFb signaling pathways func-
tionally interact. As an experimental model, we used
diploid human lung ﬁbroblasts (WI38 cells) induced by
TGFb to differentiate into myoﬁbroblast-like cells. In
order to characterize this system, we ﬁrst studied the ex-
pression of the myoﬁbroblast marker genes ACTA2
(coding for smooth muscle a-actin; SMA), COL4A1
(encoding collagen type IV a1) and SM22A (coding for
smooth muscle protein 22-a). As shown in Figure 1A and
B, TGFb induced the expression all three genes. Increased
levels of ACTA2 and COL4A1 mRNA were detectable
after 6h and reached maximum levels after 24–36h
(Figure 1A). In the same experimental setup, no signiﬁcant
effect of the PPARb/d agonists GW501516 or L165,041 on
the TGFb-mediated induction of ACTA2, COL4A1 and
SM22A was detectable (Figure 1B), suggesting that the
ligand-mediated activation of PPARb/d does not affect
the myoﬁbroblastic differentiation of WI38 cells.
Concomitantly with the induction of these marker
genes, SMA-containing stress ﬁbers, a hallmark of
differentiating myoﬁbroblasts, were readily detectable
after 24h exposure of WI38 cells to TGFb (Figure 1C).
Consistent with the marker gene expression data in
Figure 1B, treatment with the PPARb/d agonist
GW501516 had no detectable effect on stress ﬁber forma-
tion by TGFb (Figure 1D).
As the deletion of Ppard in mice has been associated
with myoﬁbroblastic differentiation in the tumor stroma,
we also investigated whether the inhibition of PPARb/d
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status of these cells. Supplementary Figure S1 shows
that ACTA2 expression indeed increased after the
siRNA-mediated knockdown of PPARb/d. Taken
together, these observations suggest that PPARb/d plays
a role in preventing myoﬁbroblastic transdifferentiation
under basal conditions, but that its activation by ligands
does not prevent TGFb-induced differentiation.
Figure 1. TGFb-induced myoﬁbroblast-like differentiation of WI38 cells is not affected by PPARb/d ligands. (A) Cells were treated with TGFb1
(2ng/ml) or solvent for the indicated times, and the relative expression levels of ACTA2 and COL4A1 were determined by RT-qPCR. ***, signiﬁcant
difference to solvent-treated sample (P<0.001 by t-test). (B) Expression of ACTA2, COL4A1 and SM22A after 24h treatment with TGFb1 (2ng/
ml), GW501516 (0.3mM), L165,041 (2mM), TGFb1 plus PPARb/d ligand (as indicated) or solvent determined by RT-qPCR. No signiﬁcant differ-
ences were detectable (t-test, P>0.1) in PPARb/d ligand-treated cells in either the absence or presence of TGFb.( C) Staining by indirect immuno-
ﬂuorescence of SMA stress ﬁbers (green) in WI38 cells treated with solvent or TGFb for 24h as in (A). Nuclei were visualized by Hoechst 33258
staining (blue). (D) Quantitative evaluation of SMA ﬁbers stained by immunoﬂuorescence after treatment of WI38 cells with TGFb or TGFb plus
GW501516 for 24h. Cells showing strong, weak or no staining were counted separately. For both samples, a total of 1500 cells in 16 microscopic
ﬁelds were counted. Error bars represent the standard deviation for individual ﬁeld counts.
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The fact that PPARb/d ligands do not affect the
TGFb-induced differentiation of WI38 cells makes this
experimental system suitable to study possible interactions
of these signaling pathways in myoﬁbroblasts without
interference by an altered differentiation state. Such inter-
actions could, for instance, affect the functional activation
or metabolic activity of these cells. We therefore used this
model to address two questions: (i) does TGFb alter the
regulation of PPARb/d target genes, and (ii) do PPARb/d
ligands impinge on TGFb-mediated transcriptional signal-
ing events that are associated with, for instance, inﬂam-
matory or ﬁbrotic responses.
To identify potential functional interactions between
TGFb and PPARb/d signaling pathways, we performed
microarray analyses of WI38 cells, either untreated
(solvent) or treated with GW501516 (0.3mM), TGFb1
(2ng/ml) or both ligands for 24h (EMBL-EBI
ArrayExpress, accession number E-MEXP-2750). As
illustrated by the Venn diagram in Figure 2A, 5039
probes indicated regulation by TGFb and 143 probes
regulation by GW501516 ( 1.3-fold change) with an
overlap of 117 probes. These correspond to 74 different
annotated genes regulated by both ligands.
To determine cooperative or antagonistic effects exerted
by TGFb and GW501516, we compared for individual
genes the transcriptional outcome of exposing WI38 cells
to both ligands to that of treatment with either ligand
alone, as described in the following sections.
Modulation of TGFb signaling by PPARb/d
The effect of GW501516 on TGFb-mediated regulation
was determined by plotting the relative expression levels
measured after co-treatment with both ligands against the
expression levels measured after treatment with TGFb
alone. The dot plot in Figure 2B identiﬁes different set
of probes showing distinct responses to TGFb and
GW501516.
‘Class A’ probes, which represent the major group
deﬁned in the present study, indicate repression by
TGFb that is counteracted by GW501516. This pattern
was observed for a total of 136 probes, including 122 dif-
ferent annotated genes (cutoff  1.3-fold upregulation by
GW501516; red data points in Figure 2B; Supplementary
Table S1). The characteristic expression pattern of class A
genes in response to TGFb and GW501516 is shown
in Figure 3A, and validated by RT-qPCR (Figure 4)
for ANGPTL4 (angiopoietin-like 4), PDK4 (pyruvate
dehydrogenase kinase 4), CPT1A (carnitine
palmitoyltransferase 1A) and ADRP (adipose
differentiation-related protein). Several representative
genes of this class are listed in Table 1.
Figure 2. Genome-wide expression proﬁling of WI38 cells treated with
TGFb, PPARb/d agonist or both ligands. (A) Venn diagram depicting
the numbers of probes showing regulation by TGFb or GW501516
( 1.3-fold change). The overlap represents those probes that indicate
regulation by both ligands. (B) Dot plot analyzing for individual probes
the effect of GW501516 on TGFb-mediated regulation. Relative expres-
sion levels measured after co-treatment of WI38 cells with TGFb plus
GW501516 were plotted against expression levels measured after treat-
ment with TGFb alone. Red data points represent probes indicating
reversion by GW501516 of TGFb-mediated repression ( 1.3-fold
upregulation; class A genes), blue data points represent probes
indicating reversion by GW501516 of TGFb-mediated activation
( 1.3-fold difference; class B genes). (C) Dot plot showing for individ-
ual probes a TGFb-mediated increased GW501516 inducibility.
Induction by GW501516 in the presence of TGFb was plotted
against the induction by GW501516 in the absence of TGFb. The
former value was calculated as the ratio of (fold induction by both
ligands) / (fold induction by TGFb). Red data points represent the
class A probes deﬁned in panel B. Triangles indicate sensitization by
TGFb, i.e. an increased induction ( 1.3-fold) by GW501516 in the
presence of TGFb (y-value/x-value  1.3). (D) Venn diagram
illustrating the overlap between class A genes and all genes induced
by GW501516 ( 30% induction, n=112). This analysis includes
only those genes, for which the effect of TGFb could be evaluated in
a statistically meaningful way. Therefore, the number of
GW501516-induced genes is higher in (A).
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GW501516 on TGFb-mediated activation. This class
encompasses 22 probes, representing 21 annotated genes
(cutoff  1.3-fold difference for TGFb plus GW501516
relative to TGFb alone; blue data points in Figure 2B;
Supplementary Table S1). Their characteristic expression
pattern in response to TGFb and GW501516 is shown in
Figure 3B. The RT-qPCR data in Figure 5 conﬁrm that
PPARb/d activation counteracts the TGFb-mediated in-
duction of the class B genes IL6 (interleukin-6), CD274
(B7-H1) and CLDN1 (claudin 1), which was clearly de-
tectable 6h after application of GW501516, pointing to a
direct effect of the PPARb/d ligands. No effect on the
TGFb-mediated induction of IL6 was seen with the
PPARg ligand GW1929 or the PPARa agonist GW7647
(Figure 5D), suggesting that the observed effect is
PPARb/d-speciﬁc.
Cooperative regulation was also detectable for several
probes (Figure 2B; not highlighted; class C and D in
Supplementary Table S1), suggesting that GW501516 is
able to inﬂuence the expression of distinct sets of both
TGFb-repressed and TGFb-activated genes in both direc-
tions. Class C includes KIT, FOXQ1 and TOP2A, which
code for the tyrosine kinase receptor KIT, the transcrip-
tion factor forkhead box Q1 and topoisomerase II, re-
spectively. All three genes have been associated with cell
cycle progression and tumorigenesis and may thus be of
particular interest with respect to the function of TGFb
and PPARb/d in tumor and tumor stroma cells.
Repression of PPARb/d target genes by TGFb and
counter-regulation by GW501516
We next determined for individual probes the effect of
TGFb on GW501516 inducibility. This was achieved by
plotting the induction by GW501516 in the presence of
TGFb (fold GW501516 plus TGFb/TGFb alone) against
the induction by GW501516 in the absence of TGFb
(Figure 2C). The predominant probe set identiﬁed by
this analysis indicates increased induction ( 1.3-fold) by
GW501516 in the presence of TGFb (shown as triangles in
Figure 2C). Surprisingly, a substantial number of these
probes are identical to those showing repression by
TGFb and counter-regulation by GW501516 (red data
points in Figure 2B and C). This overlap (Figure 2D)
includes 37% of all class A probes (45/122) and 40% of
all GW501516-induced sequences (45/112). The concomi-
tant sensitization by TGFb to activation by PPARb/d
agonists and the reversal of the repressive effect of
TGFb by these ligands is also illustrated by the data in
Figure 4 and Table 1. These ﬁndings suggest that the
TGFb-mediated repression of class A genes and its
reversal by PPARb/d agonists are functionally linked.
Enhancement of corepressor recruitment to PPAR
response elements by TGFb
Finally, we addressed the molecular mechanisms that con-
tribute to the regulation of class A genes. The activating
and repressive activities of PPARs have been linked to
Figure 3. Graphic representation of the reverse effects of GW501516 on TGFb-mediated gene regulation. The graphics show the expression patterns
for the top 10 class A and class B genes identiﬁed in Figure 2B. (A) Repression by TGFb counteracted by GW501516 (class A genes); (B) induction
by TGFb counteracted by GW501516 (class B genes).
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corepressors, which in turn have profound effects on the
local chromatin structure (9,25). Analysis of our micro-
array revealed a higher expression of several genes
encoding corepressors of nuclear receptors in
TGFb-treated cells relative to solvent controls. These
include NCOR1 (coding for NCOR), NCOR2 (encoding
SMRT), SHARP, LCOR, SIN3B, MTA1 and CALR
(Figure 6A). Previous work by several laboratories has
established a role for the corepressors NCOR and
SMRT in transcriptional repression by unliganded
PPARb/d in vivo (9,25–28). Upregulation of NCOR2 was
observed in RT-qPCR experiments already 6h after treat-
ment with TGFb, whereas the induction of NCOR1 was
statistically not signiﬁcant at this time point (Figure 6B).
We therefore analyzed whether TGFb might inﬂuence
the recruitment of SMRT to the PPREs of the ANGPTL4
gene in vivo. Figure 6C shows that this is indeed the case.
TGFb treatment induced a 2.2-fold enhanced recruitment
relative to solvent-treated cells, which was decreased to
1.3-fold in the presence of GW501516. This correlates
well with the observed changes in ANGPTL4 expression,
pointing to a causal relationship between the regulation of
class A genes and the recruitment of SMRT in response to
TGFb and GW501516.
To test this hypothesis, we analyzed the impact of
NCOR2 siRNA interference on TGFb and GW501516-
regulated ANGPTL4 and PDK4 gene expression. As
shown in Figure 7A (left), the treatment of WI38 cells
with NCOR2 siRNA reduced NCOR2 expression to
28–46% relative to cells exposed to control siRNA. The
same treatment also attenuated the TGFb-mediated
repression of both PPAR target genes, whose relative
expression levels increased in NCOR2 siRNA-treated
cells from 0.23 to 0.50 for ANGPTL4, and from 0.16 to
0.40 for PDK4 (Figure 7A and B), respectively. This
increased basal level expression was paralleled by a
decreased inducibility by PPARb/d ligands in the
presence of TGFb, which dropped by  50% for both
genes (Figure 7A and C). The fact that similar patterns
Figure 4. PPARb/d counteracts TGFb-mediated transcriptional
repression for a subgroup of target genes. Treatment of WI38
cells with TGFb and/or PPARb/d ligands for 24h and
RT-qPCR analyses of ANGPTL4 (A), PDK4 (B), ADRP
(C) and CPT1A (D) expression were performed as in Figure 1B.
***, **, * signiﬁcant difference (P<0.001 by t-test, P<0.01,
P<0.05).
Table 1. Representative examples of PPARb/d target genes regulated by TGFb-mediated repression and reversal by GW501516 (class A genes)
Gene Gene product TGFb
a GW501516
a (GW501516 +
TGFb) / TGFb
b
ANGPTL4 Angiopoietin-like 4 0.3 6.5 18.9
PDK4 Pyruvate dehydrogenase kinase, isozyme 4 0.4 4.7 4.1
CPT1A Carnitine palmitoyltransferase 1A 0.5 2.0 3.2
DDEF1IT1 DDEF1 intronic transcript 1 0.7 1.5 2.8
GPR137B G-protein-coupled receptor 137B 0.4 1.6 2.6
SP100 SP100 nuclear antigen 0.5 1.3 2.5
SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 0.5 1.4 2.3
IMPA2 Inositol(myo)-1(or 4)-monophosphatase 2 0.3 1.7 2.2
ACAA2 Acetyl-Coenzyme A acyltransferase 2 0.7 1.4 2.0
ABCA1 ATP-binding cassette, sub-family A, member 1
(cholesterol transporter)
0.6 1.5 1.9
ADRP Adipose differentiation-related protein 0.4 1.8 1.9
CAT Catalase 0.4 1.5 1.8
aRelative expression values derived from microarray data (fold induction relative to solvent-treated cells).
bValues reﬂect GW501516-mediated induction in the presence of TGFb corrected for the TGFb effect.
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the regulatory mechanism identiﬁed in this study is not
gene-speciﬁc. Taken together, these observations clearly
establish a functional connection between SMRT, TGFb
and the transcription of PPARb/d target genes.
DISCUSSION
Several lines of evidence strongly suggest that PPARb/d
plays a role in regulating the differentiation and function
of tumor stroma and inﬂammatory cells, pointing to a
crosstalk of PPARb/d and cytokine signaling pathways.
A cytokine with a pivotal function in inﬂammation and
tumorigenesis is TGFb. In the present study, we tested this
hypothesis by asking whether PPARb/d and TGFb signal-
ing pathways functionally interact and modulate the tran-
scriptional activity of common target genes in diploid
human ﬁbroblasts induced to differentiate into
myoﬁbroblast-like cells.
Reverse crosstalk of TGFb and PPARb/d signaling
The potential interaction of transcriptional signaling
pathways regulated by PPARb/d and TGFb was
analyzed by determining the genome-wide transcriptional
proﬁle of WI38 cells treated with TGFb, a PPARb/d
agonist or both ligands. The data obtained from this
analysis point to an extensive crosstalk of the transcrip-
tional signaling pathways regulated by PPARb/d and
TGFb (Figures 2 and 3). Bioinformatic analyses identiﬁed
several classes of genes showing distinct responses to the
combined action of TGFb and PPARb/d agonists. Two of
these classes that are of particular interest are
characterized by the following distinct features
(Figures 2B and 3): (i) repression by TGFb, which is coun-
teracted by PPARb/d agonists (class A genes; Table 1),
Figure 5. PPARb/d agonists inhibit TGFb-mediated transcriptional activation for a subgroup of target genes. WI38 cells were treated with the
PPARb/d ligands GW501516 and L165,041 for 16h, subsequently stimulated with TGFb for 6 or 24h, and CLDN1 (A), CD274 (B) and IL6 (C)
expression was analyzed by RT-qPCR. (D) Comparison of the effects of the PPARb/d ligand L165,041, the PPARg ligand GW1929 and the PPARa
agonist GW7647 on TGFb-mediated induction of IL6. ***, **, * signiﬁcant difference (P<0.001 by t-test, P<0.01, P<0.05).
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PPARb/d agonists (class B genes). In both cases,
PPARb/d agonists signiﬁcantly inhibited the effect of
TGFb, indicating that this mode of interaction is a
major feature of the interaction of these pathways.
Repression of PPARb/d target genes by TGFb and
reversal by GW501516
We also determined for individual probes the effect of
TGFb on ligand-mediated PPARb/d activation. This
analysis identiﬁed a major set of genes, representing
mostly classical PPAR target genes, such as ANGPTL4,
PDK4, ADRP and CPT1A, which show increased induc-
tion by GW501516 in the presence of TGFb (Figure 2C).
These genes overlap to a large extent (37%) with class A
genes (red data points in Figure 2B and C), indicating that
the enhancement of GW501516 inducibility by TGFb is
functionally linked to their repression by TGFb.
It has previously been shown that the ANGPTL4 gene is
induced by TGFb in human breast cancer cell lines (21),
which is in apparent contrast to the ﬁndings reported in
the present study. It is, however, well established that
TGFb frequently exerts opposite effects on target gene
expression in mesenchymal and epithelial cells, and that
neoplastic transformation can subvert TGFb-mediated
transcriptional regulation (29). It would thus be conceiv-
able that the ANGPTL4 gene is also subject to a similarly
complex regulatory network. Consistent with this hypoth-
esis is our observation (30) that ANGPTL4 transcription is
induced by TGFb in the epithelial cell line HaCaT (31)
and in WPMY-1 cells, which is a SV40-transformed cell
line derived from human prostate carcinoma-associated
ﬁbroblasts (32). These ﬁndings suggest that the
ANGPTL4 gene is a useful model to investigate the mo-
lecular mechanisms underlying the cell type-speciﬁc and
transformation-dependent effects of TGFb-triggered tran-
scriptional signaling pathways.
Correlation of the TGFb/GW501516-mediated crosstalk
with recruitment of the transcriptional corepressor SMRT
In the absence of ligands, PPARb/d target genes can be
repressed through the recruitment of corepressors to
Figure 6. TGFb induces corepressor expression and recruitment to the PPRE enhancer of the ANGPTL4 gene in vivo.( A) Microarray data were
analyzed for TGFb-mediated effects on potential corepressor genes and plotted as relative expression values (TGFb treatment versus solvent control).
The dashed line denotes a threshold of 1.3-fold induction. (B) RT-qPCR analysis of NCOR1 and SMRT expression 6h following treatment of WI38
cells with GW501516, TGFb1 or both ligands. (C) TGFb induces SMRT recruitment to the ANGPTL4 PPRE enhancer in vivo. WI38 cells were
treated with 0.3mM GW501516, 2ng/ml TGFb1, or both for 24h, and ChIP was carried out with antibodies against PPARb/d, SMRT or a
nonspeciﬁc IgG pool, and an ANGPTL4 region containing the PPRE enhancer (+3500bp relative to the transcription start site) was ampliﬁed by
qPCR. An ANGPTL4 upstream region was included as a control. Signals were calculated relative to 1% of input DNA. **, * signiﬁcant difference to
solvent-treated sample (P<0.01 by t-test, P<0.05).
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NCOR and SMRT (9,25–28). In the present study, we
tested the hypothesis that TGFb may enhance the forma-
tion or function of these repressor complexes. In such a
scenario, TGFb would lead to a decreased transcriptional
activity in the absence of ligands, and PPARb/d agonists
induce the dissociation of corepressors and their replace-
ment with coactivators, thereby counteracting the TGFb
effect. Our data are consistent with this model: (i) the
NCOR2 gene (coding for SMRT) is a transcriptional
Figure 7. NCOR2 induction plays a role in the TGFb-triggered repression of PPARb/d target genes. (A) WI38 cells were transfected with NCOR2 or
control siRNA as described in ‘Materials and Methods’ section. Twenty-four hours after serum deprivation the cells were treated with TGFb1 (2ng/
ml), TGFb1+GW501516 (0.3mM), TGFb1+L165,041 (2mM) or solvent for 10h, and NCOR2, ANGPTL4 and PDK4 mRNA levels were measured
by RT-qPCR. The lower inducibility by GW501516 as compared to Figure 4 is presumably due to different cell densities and the siRNA treatment.
(B) Effect of siRNA treatment on TGFb-mediated ANGPTL4 and PDK4 repression. Values represent the ratio of expression levels in solvent-treated
cells relative to TGFb-treated cells. Experimental details as in (A). (C) Effect of siRNA treatment on PPARb/d ligand-mediated ANGPTL4 and
PDK4 induction in the presence of TGFb. Values represent the ratio of expression levels in cells treated with PPARb/d ligands plus TGFb relative to
TGFb-treated cells. Experimental details as in (A). ***, **, * signiﬁcant difference to solvent-treated (A) or si-con (B, C) sample (P<0.001 by t-test,
P<0.01, P<0.05).
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NCOR2 expression leads to an increased recruitment of
the SMRT corepressor to the ANGPTL4 PPREs in vivo
(Figure 6C); (iii) this enhancement of SMRT recruitment
is markedly diminished by the PPARb/d agonist
GW501516 (Figure 6C); (iv) the siRNA-mediated inhib-
ition of NCOR2 expression leads to a strong derepression
of ANGPTL4 transcription and an inhibition of
TGFb-mediated repression (Figure 7A and B); and (v)
the same treatment also reduced the inducibility by
PPARb/d ligands in the presence of TGFb (Figure 7A
and C). These ﬁndings provide compelling evidence for a
functional link between the TGFb-induced expression of
SMRT, the impact of TGFb on PPARb/d target genes
and the counteracting effects of PPARb/d ligands.
Importantly, similar siRNA effects were also observed
with another class A gene, the PPARb/d target gene
PDK4 (Figures 4 and 7). This suggests that the regulatory
mechanism identiﬁed here is not a peculiar feature of
the ANGPTL4 gene, but appears to a have a broader
relevance. Collectively, our ﬁndings establish a clear
functional connection between the induction of
corepressor expression by TGFb and the transcription
of PPARb/d target genes, as are illustrated by the model
in Figure 8.
The data in Figure 7A and C indicate that after
knockdown of NCOR2 expression, TGFb still represses
ANGPTL4 and PDK4 transcription, albeit to a reduced
extent. This suggests that SMRT may not be the only
corepressor relevant in this context, and that the
PPARb/d repressor complex is probably subject to add-
itional regulatory mechanisms triggered by TGFb. This is
supported by the observation that the overall expression
level induced by PPARb/d ligands is higher than that
observed after treatment with ligand plus TGFb (Figure
4). Consistent with this hypothesis, TGFb induces several
other corepressor genes, such as CALR (calreticulin),
LCOR, MTA1, SHARP and SIN3B (Figure 6A), which
may play a role in the formation of PPARb/d repressor
complexes, as previously published for SHARP (9,25–28).
The clariﬁcation of these questions will be the subject of
future studies aiming at a precise dissection of the molecu-
lar mechanism involved in the regulation of class A genes
by PPARb/d and TGFb.
Inhibition of TGFb-mediated transcriptional activation
by PPARb/d ligands
The genes represented by the second group are induced
by TGFb, which is diminished by PPARb/d agonists
(Figure 2B, blue data points). This group contains
several genes that are potentially relevant in view of the
known function of PPARb/d in modulating the immune
responses. One of these is interleukin-6, a cytokine with
both pro-inﬂammatory and anti-inﬂammatory properties
and a vast range of biological and pathophysiological
activities, including a role in tissue ﬁbrosis (33). Time
course experiments suggest that repression of
TGFb-mediated IL6 induction by PPARb/d ligands is a
direct event, because it is detectable within 6h
post-treatment (Figure 5C). The IL6 gene is regulated by
Figure 8. Model illustrating the repression of the PPARb/d target genes by TGFb and its reversion by PPARb/d ligands. CoA, coactivator; CoR,
corepressor; CoReg, activating or repressing coregulators; orange squares, synthetic PPARb/d ligand (GW501516). (Left) the absence of both
GW501516 and TGFb leads to a weak recruitment of positive and negative coregulators, resulting in a low rate of transcription. (Middle) TGFb
induces corepressor genes, including NCOR2, which leads to an enhanced recruitment of SMRT and other corepressors (CoR) to PPRE-bound
PPARb/d complexes, and consequently an inhibition of transcription. (Bottom) GW501516 induces SMRT dissociation and favors the association
with coactivators, leading to transcriptional activation. (Top) Other corepressors (CoR) induced by TGFb, like those identiﬁed in Figure 6A, remain
bound to the PPARb/d, resulting in a lower level of transcription compared to cells exposed to PPARb/d ligands in the absence of TGFb.
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C/EBP, which have been suggested to interact with
PPARs in different experimental systems (34,35). It is
possible that the inhibitory effect of PPARb/d on
TGFb-induced IL6 transcription is also associated with
these transcription factors. Another potentially interesting
gene in this context is CD274 coding for B7-H1, a
membrane-bound ligand that modulates the activation
or inhibition of lymphocytes and myeloid cells (36).
Taken together, these data suggest that in differentiating
myoﬁbroblasts PPARb/d agonists counteract the effects
of TGFb for a subset of target genes with functions
in immune regulation, highlighting the relevance of
these compounds as potential anti-ﬁbrotic and anti-
inﬂammatory drugs.
Cooperative signaling by TGFb and PPARb/d
We also detected cooperation of the two signaling
pathways for several genes (Supplementary Table S1;
class C and D). The cooperatively repressed genes (class
C) include the cell cycle and tumorigenesis promoting
genes KIT, FOXQ1 and TOP2A. This is of potential
interest, because we observed cooperative effects of
TGFb and GW5101516 also on cell-cycle regulation.
Thus, GW501516 not only inhibited cell-cycle progression
in untreated WI38 cells, but also enhanced the inhibitory
effect of TGFb (Figure S2). The cooperative regulation of
genes that have been associated with the cell cycle may
thus provide an explanation for the cooperation of
GW501516 and TGFb in the inhibition of cell-cycle pro-
gression. However, it cannot be ruled out at present that
the cell-cycle effects mediated by the two ligands are
functionally unrelated. Inhibition of cell proliferation
by PPARb/d ligands has previously been reported for a
number of other cell lines of different origins, but
the underlying molecular mechanisms remain largely
obscure (10).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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